期刊文献+

利塞膦酸钠对绝经后骨质疏松症骨密度和骨代谢的影响 被引量:6

下载PDF
导出
摘要 目的:探讨利塞膦酸钠(RID)对绝经后骨质疏松症骨密度(BMD)和骨代谢的影响。方法:24例绝经后骨质疏松症患者采用自身治疗前后对照方式进行12个月的药物研究。患者每日服用RID片5mg,用双能量X线骨密度测量仪比较治疗前和治疗后6、12个月腰椎及髋部BMD改变,同时检测骨代谢生化指标血清骨钙素(BGP)及尿I型胶原交联氨基末端肽(NTX)在治疗前后的变化。结果:治疗后6个月和12个月腰椎2~4BMD均明显增加,与治疗前相比差异有统计学意义(P<0.05);股骨颈BMD治疗后12个月较治疗前增加(P<0.05);治疗后6个月及12个月BGP及NTX较治疗前明显降低(P<0.01)。结论:RID能增加绝经后骨质疏松症患者腰椎和股骨颈BMD,显著降低骨转换率,抑制骨吸收。
出处 《广西医科大学学报》 CAS 北大核心 2008年第5期737-738,共2页 Journal of Guangxi Medical University
  • 相关文献

参考文献9

  • 1Ross FP. Interleukin 7 and estrogen-induce bone loss [J]. Trends Endoerinol Metab, 2003, 14(4)147-149.
  • 2吕靖,马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述,2007,13(1):62-63. 被引量:37
  • 3Crandall C. Risedronate a clinical review[J]. Arch Intern Med, 2001, 161(3): 353-360.
  • 4Chapurlat RD, Delmas PD. Risedronate clinical usage [J]. Int J Clin Pract,2001,55:275-278.
  • 5姚斌,李建娟,黄俭强,许雯,胡国亮,翁建平,梁奕铨.利塞膦酸钠在防治退休护士绝经后骨质疏松症中的作用[J].中国医师杂志,2004,6(12):1704-1705. 被引量:1
  • 6McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group[J]. N Engl J Med,2001,344:333-340.
  • 7李裕明,张众志,邓秀玲,王琳芳,陈璐璐.利塞膦酸钠治疗绝经后骨质疏松症的疗效及安全性[J].中国骨质疏松杂志,2006,12(1):62-65. 被引量:8
  • 8Raisz L, Smith JA, Trahiotis M,et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover[J]. Osteoporos Int, 2000,11(7):615-620.
  • 9Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate[J]. J Bone Miner Res, 2003,18(6):1 051-1 056.

二级参考文献41

  • 1杨玲,殷晓进.锶与骨矿代谢[J].中国骨质疏松杂志,2004,10(3):384-387. 被引量:17
  • 2Fogelman I, Ribot C, Smith R, et al. Risedronate reverse bone loss in postmenopaual women with low bone mass: results from a multination, double-blind, placebo-controll trial[J]. J Clin Endocrinol Metab, 2000,85(5):1895-1900
  • 3Reginster JY, Minne HW, Sorense OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis[J]. Osteoporos Int,2000,11:83-91
  • 4Mc Clung M, Gueusens P, Miller PD, et al. Risedronate reduces hip fracture risk in elderly women with osteoporosis[J]. N engl J med,2001,344:333-340
  • 5Seeman E, Eisman JA. Treatment of osteoporosis: Why,whom,who and how to treat[J].Med J Aust,2004,180(6):298-303
  • 6Hundrup YA, Erik BO, Rasmussen NK, et al. Use of hormone replacement therapy among Danish nurses in 1993[J]. Acta Obstet Gynecol Scand,2000,79:194-201
  • 7Carolyn Crandall. Risedronate - A clinical review[J]. Arch Intern Med,2001,161(3):353-360
  • 8Mortensen L, Chines A, Myers WR, et al. Risedronate increasease bone mass in an early postmenopausal populution: two years of treatment plus one year of follow[J]. J Clin Endocrinol Metab, 1998,83(2):396-405
  • 9Ogura Y, Gonsho A, Cyong TC, et al. Clinical trial of risedronate in Japanese volunteers : single and multiple oral dose studies[J].J Bone Miner Metab,2004,22(2):111-119
  • 10Chapurlat RD, Delmas PD. Risedronate:Clinical usage[J]. Int J clin pract, 2001, 55(4):275-278

共引文献42

同被引文献83

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部